Craig-Hallum Bullish on Compass Therapeutics: Buy Rating & $15 Target

Investment firm Craig-Hallum starts coverage on Compass Therapeutics with a Buy rating and $15 price target, highlighting its promising bispecific antibody pipeline and potential blockbuster in biliary tract cancer.